{"id":3641,"date":"2020-10-01T21:41:23","date_gmt":"2020-10-01T19:41:23","guid":{"rendered":"https:\/\/aa-pnh.pe-dev.de\/results-of-race-trial\/"},"modified":"2022-05-16T17:18:32","modified_gmt":"2022-05-16T15:18:32","slug":"results-of-race-trial","status":"publish","type":"post","link":"https:\/\/aa-pnh.org\/en\/results-of-race-trial\/","title":{"rendered":"Results of RACE trial"},"content":{"rendered":"<p>The <a href=\"https:\/\/www.ebmt.org\/\" rel=\"noopener noreferrer\" target=\"_blank\">EBMT<\/a> (European Society for Blood and Marrow Transplantation) conducts the RACE clinical trial to evaluate the combined therapy of equine <a class=\"glossaryLink\"  aria-describedby=\"tt\"  data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;ATG&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;ATG; immunosuppressive mixture of antibodies obtained from rabbits or horses. It reduces the number of lymphocytes (lymphocytopenia), mainly by suppressing circulating T-lymphocytes. It is used for instance to treat aplastic anaemia and for the prophylaxis and therapy of GvHD in the context of(...)&lt;\/div&gt;\"  href=\"https:\/\/aa-pnh.org\/en\/glossar\/atg\/\"  data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]'  tabindex='0' role='link'>ATG<\/a>, <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;ciclosporin&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Also known as cyclosporin A, CsA; immunosuppressive medication administered e.g. to treat aplastic anaemia and prevent GvHD disease. In high doses and with long-term administration, its main side effects are hypertension, tremor of the hands and deterioration of kidney function. Blood levels(...)&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/ciclosporin\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">ciclosporin<\/a> and eltrombopag in patients with severe or very severe Aplastic <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;Anaemia&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Reduction of red blood cells or their content of (blood pigment); as a result of blood loss, reduced haemoglobin production, reduced blood cell development due to bone marrow diseases, increased blood cell decay due to poisoning and metabolic disorders. Anaemia leads to reduced physical capacity. &lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/anaemia\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">Anaemia<\/a>. &ldquo;RACE&rdquo; means &ldquo;A prospective <strong>R<\/strong>andomized multicenter study comparing horse <strong>A<\/strong>ntithymocyte globuline (h<a class=\"glossaryLink\"  aria-describedby=\"tt\"  data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;ATG&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;ATG; immunosuppressive mixture of antibodies obtained from rabbits or horses. It reduces the number of lymphocytes (lymphocytopenia), mainly by suppressing circulating T-lymphocytes. It is used for instance to treat aplastic anaemia and for the prophylaxis and therapy of GvHD in the context of(...)&lt;\/div&gt;\"  href=\"https:\/\/aa-pnh.org\/en\/glossar\/atg\/\"  data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]'  tabindex='0' role='link'>ATG<\/a>) + <strong>C<\/strong>yclosporine A (CsA) with or without <strong>E<\/strong>ltrombopag as front-line therapy for severe <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;aplastic&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Condition of the non-functional bone marrow that cannot develop blood cells&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/aplastic\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">aplastic<\/a> anemia patients&rdquo;.<\/p>\n<p>Results of the <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000363-40\/NL\" rel=\"noopener noreferrer\" target=\"_blank\">trial (in the Netherlands by way of example)<\/a> show good response rates in the patients who received all three medicines. In Germany, the trial must not be conducted because of missing admissions. However, we consider it to be important to watch the trial data in order to use it ind admission discussions with authorities.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The EBMT (European Society for Blood and Marrow Transplantation) conducts the RACE clinical trial to evaluate the combined therapy of equine <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;ATG&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;ATG; immunosuppressive mixture of antibodies obtained from rabbits or horses. It reduces the number of lymphocytes (lymphocytopenia), mainly by suppressing circulating T-lymphocytes. It is used for instance to treat aplastic anaemia and for the prophylaxis and therapy of GvHD in the context of(...)&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/atg\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">ATG<\/a>, <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;ciclosporin&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Also known as cyclosporin A, CsA; immunosuppressive medication administered e.g. to treat aplastic anaemia and prevent GvHD disease. In high doses and with long-term administration, its main side effects are hypertension, tremor of the hands and deterioration of kidney function. Blood levels(...)&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/ciclosporin\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">ciclosporin<\/a> and eltrombopag in patients with severe or very severe Aplastic <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;Anaemia&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Reduction of red blood cells or their content of (blood pigment); as a result of blood loss, reduced haemoglobin production, reduced blood cell development due to bone marrow diseases, increased blood cell decay due to poisoning and metabolic disorders. Anaemia leads to reduced physical capacity. &lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/anaemia\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">Anaemia<\/a>. &ldquo;RACE&rdquo; means &ldquo;A prospective Randomized multicenter study comparing horse <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;Antithymocyte globulin&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;ATG; immunosuppressive mixture of antibodies obtained from rabbits or horses. It reduces the number of lymphocytes (lymphocytopenia), mainly by suppressing circulating T-lymphocytes. It is used for instance to treat aplastic anaemia and for the prophylaxis and therapy of GvHD in the context of(...)&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/antithymocyte-globulin\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">Antithymocyte globulin<\/a>e&hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"gallery","meta":{"footnotes":""},"categories":[82,86,81],"tags":[],"class_list":["post-3641","post","type-post","status-publish","format-gallery","hentry","category-clinical-studies","category-illness","category-medication","post_format-post-format-gallery"],"_links":{"self":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/posts\/3641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/comments?post=3641"}],"version-history":[{"count":0,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/posts\/3641\/revisions"}],"wp:attachment":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/media?parent=3641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/categories?post=3641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/tags?post=3641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}